Trial of the Reactogenicity, Safety and Immunogenicity of the Flu-M Vaccine Manufactured by FSUE SPbSRIVS FMBA
Phase 2
Completed
- Conditions
- Influenza
- Interventions
- Biological: Inactivated influenza split vaccineBiological: Flu-M [Inactivated split influenza vaccine]
- First Posted Date
- 2022-03-28
- Last Posted Date
- 2022-03-28
- Target Recruit Count
- 400
- Registration Number
- NCT05297994
- Locations
- 🇷🇺
Infection Center, Novosibirsk, Russian Federation
🇷🇺Perm State Medical University named after Academician E. A. Wagner, Perm, Russian Federation
🇷🇺Research Institute of Influenza, Saint Petersburg, Russian Federation
Study of the Immunogenicity, Safety and Tolerability of the Convacell Vaccine.
Phase 1
Completed
- Conditions
- COVID-19Respiratory Tract InfectionsImmunologic FactorsCoronavirus Infections
- Interventions
- Biological: Subunit recombinant vaccine for the prevention of coronavirus infectionBiological: Placebo
- First Posted Date
- 2021-12-14
- Last Posted Date
- 2023-08-30
- Target Recruit Count
- 155
- Registration Number
- NCT05156723
- Locations
- 🇷🇺
Medvitro, LLC, Moscow, Russian Federation
🇷🇺Eco-Safety, LLC, Saint-Petersburg, Russian Federation
🇷🇺Research Institute of Vaccines and Serums them. I.I. Mechnikov, Moscow, Russian Federation
The Objectives of This Study Are Study the Safety, Reactogenicity and Obtain Preliminary Data on the Immunogenicity of Flu-M Quadro, 4-valent Inactivated Split Influenza Vaccine, in Healthy Volunteers
Phase 1
Completed
- Conditions
- Influenza
- Interventions
- Biological: Flu-M Quadro [inactivated split influenza vaccine] with preservativeBiological: PlaceboBiological: Flu-M Quadro [inactivated split influenza vaccine] without preservative
- First Posted Date
- 2021-12-09
- Last Posted Date
- 2022-01-06
- Target Recruit Count
- 75
- Registration Number
- NCT05152017
- Locations
- 🇷🇺
Federally Funded Healthcare Institution Primary Healthcare Unit No. 163, Novosibirsk, Russian Federation
The Objectives of This Study Are Study of the Reactogenicity, Safety and Immunogenicity of Flu-M Inactivated Split Influenza Vaccine in Volunteers Aged 18-60 Years
Phase 1
Completed
- Conditions
- Influenza
- Interventions
- Biological: Inactivated Split Influenza VaccineBiological: Placebo
- First Posted Date
- 2021-11-19
- Last Posted Date
- 2022-01-06
- Target Recruit Count
- 45
- Registration Number
- NCT05126979
- Locations
- 🇷🇺
Perm State Medical University named after academician E.A. Wagner, Perm, Russian Federation
The Objectives of This Study Are Study the Immunogenicity and Safety of the Flu-M [Inactivated Split Influenza Vaccine], vs. the Ultrix® Inactivated Split Influenza Vaccine, in Volunteers Who Are Over 60 Years Old
Phase 3
Completed
- Conditions
- Influenza
- Interventions
- Biological: Flu-M [Inactivated split influenza vaccine]Biological: Inactivated Split Influenza Vaccine
- First Posted Date
- 2021-10-22
- Last Posted Date
- 2022-01-06
- Target Recruit Count
- 320
- Registration Number
- NCT05089123
- Locations
- 🇷🇺
LLC "Strategicheskie Meditsinskie Sistemi", Saint Petersburg, Russian Federation
🇷🇺LLC "Meditsinskie Tehnologii", Saint Petersburg, Russian Federation
© Copyright 2025. All Rights Reserved by MedPath